The problem with molecular infection diagnosis is that conventional DNA isolation generates a mixture of human DNA and pathogen DNA the former being in great excess to the target. This in turn can result in unspecific PCR signals and a decrease in detection sensitivity as a consequence of primer binding to sites on the human DNA.

To face this problem, Molzym has developed a technology, MolYsis, that nearly quantitatively (>99%) removes human non-target DNA from whole blood and other clinical samples while DNA is isolated from pathogen cells. The procedure is very simple and comprises a short pre-treatment of the sample, thereafter discharged into the used DNA isolation procedure.